Loading...
•
Jun 30, 2023
Vir Q2 2023 Earnings Report
Reported a net loss due to increased R&D expenses, offset by grant revenue and focus on monoclonal antibody platform.
Key Takeaways
Vir Biotechnology reported a net loss of $194.8 million for the second quarter of 2023. The company is prioritizing its monoclonal antibody platform and advancing its pipeline programs, with data readouts expected in Q4 for chronic hepatitis B and hepatitis delta programs. Vir had $1.9 billion in cash, cash equivalents, and investments as of June 30, 2023.
Phase 2 data readouts for chronic hepatitis B and chronic hepatitis delta programs are on track for Q4 2023.
Increased focus on proprietary antibody platform and discontinuation of Vir’s innate immunity small molecule platform.
First participant to be dosed in Phase 1 trial of next-generation HIV vaccine, VIR-1388, anticipated in Q3.
Company held $1.9 billion in cash, cash equivalents and investments as of June 30, 2023.
Revenue by Segment
Forward Guidance
Vir Biotechnology is focused on advancing its monoclonal antibody platform and pipeline programs, with key data readouts expected in the near term. The company anticipates continued progress in its clinical trials and collaborations.
Positive Outlook
- Phase 2 data readouts from ongoing chronic hepatitis B and chronic hepatitis delta programs on track for Q4 2023
- First participant to be dosed in Phase 1 trial of next-generation HIV vaccine, VIR-1388, anticipated in Q3
- Multiple trials evaluating the potential for VIR-2218 and VIR-3434 to achieve a functional cure for CHB are on track with data expected in Q4 2023
- The Phase 2 SOLSTICE trial evaluating VIR-2218 and VIR-3434 as monotherapy and in combination for the treatment of people living with CHD remains on track with initial data expected in Q4 2023
- Vir is continuing to advance next-generation monoclonal antibodies (mAbs) based on its proprietary platform and enabled by AI and machine-learning capabilities to deliver high-quality solutions more efficiently.
Challenges Ahead
- In July, Vir reported that the Phase 2 Prevention of Illness Due to Influenza A (PENINSULA) trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...